Clinical utility of HPV genotyping

Chris J. Meijer, Peter J. Snijders, Philip E. Castle

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

In summary, cervical cancer screening is now entering a new era in which we will increasingly rely on measuring the causal viral infection, oncogenic HPV, rather than the pleomorphic cellular changes caused by the infection. As successive cohorts of women receive HPV vaccination, periodic screening with HPV tests will provide a useful means to monitor the duration of protection in the population. As we move from cytology-based screening to HPV-based screening, genotyping may prove useful in stratifying HPV+ women according to risk of prevalent or incipient precancer and cancer to determine the appropriate clinical management strategy. However, to achieve benefit to patients, the addition of HPV genotyping to cervical cancer screening must not be abused by excessive referrals to colposcopy and over-treatment, which can be exacerbated by the use of poorly validated tests.

Original languageEnglish (US)
Pages (from-to)12-17
Number of pages6
JournalGynecologic Oncology
Volume103
Issue number1
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Early Detection of Cancer
Uterine Cervical Neoplasms
Colposcopy
Virus Diseases
Cell Biology
Vaccination
Referral and Consultation
Infection
Population
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Clinical utility of HPV genotyping. / Meijer, Chris J.; Snijders, Peter J.; Castle, Philip E.

In: Gynecologic Oncology, Vol. 103, No. 1, 10.2006, p. 12-17.

Research output: Contribution to journalArticle

Meijer, Chris J. ; Snijders, Peter J. ; Castle, Philip E. / Clinical utility of HPV genotyping. In: Gynecologic Oncology. 2006 ; Vol. 103, No. 1. pp. 12-17.
@article{6ac4dc2ad20c41b3aaac8280c0b80d00,
title = "Clinical utility of HPV genotyping",
abstract = "In summary, cervical cancer screening is now entering a new era in which we will increasingly rely on measuring the causal viral infection, oncogenic HPV, rather than the pleomorphic cellular changes caused by the infection. As successive cohorts of women receive HPV vaccination, periodic screening with HPV tests will provide a useful means to monitor the duration of protection in the population. As we move from cytology-based screening to HPV-based screening, genotyping may prove useful in stratifying HPV+ women according to risk of prevalent or incipient precancer and cancer to determine the appropriate clinical management strategy. However, to achieve benefit to patients, the addition of HPV genotyping to cervical cancer screening must not be abused by excessive referrals to colposcopy and over-treatment, which can be exacerbated by the use of poorly validated tests.",
author = "Meijer, {Chris J.} and Snijders, {Peter J.} and Castle, {Philip E.}",
year = "2006",
month = "10",
doi = "10.1016/j.ygyno.2006.07.031",
language = "English (US)",
volume = "103",
pages = "12--17",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical utility of HPV genotyping

AU - Meijer, Chris J.

AU - Snijders, Peter J.

AU - Castle, Philip E.

PY - 2006/10

Y1 - 2006/10

N2 - In summary, cervical cancer screening is now entering a new era in which we will increasingly rely on measuring the causal viral infection, oncogenic HPV, rather than the pleomorphic cellular changes caused by the infection. As successive cohorts of women receive HPV vaccination, periodic screening with HPV tests will provide a useful means to monitor the duration of protection in the population. As we move from cytology-based screening to HPV-based screening, genotyping may prove useful in stratifying HPV+ women according to risk of prevalent or incipient precancer and cancer to determine the appropriate clinical management strategy. However, to achieve benefit to patients, the addition of HPV genotyping to cervical cancer screening must not be abused by excessive referrals to colposcopy and over-treatment, which can be exacerbated by the use of poorly validated tests.

AB - In summary, cervical cancer screening is now entering a new era in which we will increasingly rely on measuring the causal viral infection, oncogenic HPV, rather than the pleomorphic cellular changes caused by the infection. As successive cohorts of women receive HPV vaccination, periodic screening with HPV tests will provide a useful means to monitor the duration of protection in the population. As we move from cytology-based screening to HPV-based screening, genotyping may prove useful in stratifying HPV+ women according to risk of prevalent or incipient precancer and cancer to determine the appropriate clinical management strategy. However, to achieve benefit to patients, the addition of HPV genotyping to cervical cancer screening must not be abused by excessive referrals to colposcopy and over-treatment, which can be exacerbated by the use of poorly validated tests.

UR - http://www.scopus.com/inward/record.url?scp=33748573016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748573016&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2006.07.031

DO - 10.1016/j.ygyno.2006.07.031

M3 - Article

C2 - 16934860

AN - SCOPUS:33748573016

VL - 103

SP - 12

EP - 17

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -